Literature DB >> 7028411

Cefuroxime and ampicillin compared in a double-blind study in the treatment of lower respiratory tract infections.

A Pines, H Raafat, M Khorasani, B M Mullinger.   

Abstract

Cefuroxime and ampicillin were compared in a randomized double-blind trial in the treatment of severe lower respiratory tract infections. 750 mg of cefuroxime were given to 57 patients and 500 mg of ampicillin to 54 patients by intramuscular injection three times daily for 7-10 days. The patients had acute exacerbations of chronic bronchitis with or without pneumonia, a few had bronchiectasis and an underlying bronchial carcinoma was present in nearly a quarter. By the end of treatment the sputum, initially always mucopurulent, had become mucoid in 87.7% of patients receiving cefuroxime in comparison to 48.1% of those receiving ampicillin. A satisfactory clinical response was observed in 94.7 and 68.5%, respectively. Both these differences between cefuroxime and ampicillin are statistically significant (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028411     DOI: 10.1159/000238016

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  4 in total

Review 1.  New drugs in respiratory disorders: II.

Authors:  D C Flenley
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-19

Review 2.  Treatment of respiratory tract infections with cephalosporin antibiotics.

Authors:  R Finch
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

Review 4.  Head-to-head trials of antibiotics for bronchiectasis.

Authors:  Axel Kaehne; Stephen J Milan; Lambert M Felix; Emer Sheridan; Paul A Marsden; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2018-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.